GlassScriptPhysician profile
Jonathan Jalali
NPI 1548840929
$672.61
in general payments reported to CMS, 2019-2025
6 companies · $573 in 2025
The $573 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $100 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst Pharmaceuticals, INC. | $150.80 | 2025 | Orladeyo |
| Biocryst US Sales Co., LLC | $149.97 | 2025 | Orladeyo |
| Glaxosmithkline, LLC. | $121.08 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $120.17 | 2025 | Dupixent |
| Genzyme Corporation | $100.10 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Jalali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.